艾昆纬-中东与非洲医药市场季刊（英）-2025.1_28页_1mb

Middle East & Africa Pharmaceutical Business Insights (34th Edition, Jan 2025)

Core Content Overview

This report provides a comprehensive analysis of the pharmaceutical market in the Middle East & Africa (MEA) region for the period MAT Q3 2024, highlighting growth trends, market share distribution, and key therapeutic areas (TAs) and corporations. It also includes future forecasts and insights into consumer and institutional data collection methods.

Key Market Trends

• Total Value Sales: The MEA pharmaceutical business reached $33.9 B with 8.7 B Units in MAT Q3 2024.
• Value Sales Growth: Increased by 12.2% PPG and 9.6% CAGR (MAT Q3 2020–2024).
• Volume Sales Growth: Declined by -0.7% PPG but increased by 1.6% CAGR.
• Retail Channel Dominance: Accounts for 68.9% of total value sales ($23.3 B) and 81.8% of total volume sales (7.0 B Units), with 13.9% PPG growth.
• Hospital Channel: Grew by 8.6% PPG in value and -8.1% PPG in volume.

Country Performance

KSA (Saudi Arabia)

• Value Growth: 11.1% PPG, leading the region with $12.4 B in sales.
• Retail Channel: Holds 48.4% of total market sales, growing at 5.0% PPG.
• Top Corporations: Hikma Pharma leads with 6.3% market share and 4.1% PPG growth. Jamjoom Pharma is the fastest-growing local/regional company with 27.1% PPG.

UAE

• Value Growth: 17.5% PPG, the fastest-growing country in the region.
• Top TAs: Newer Gen Type II Antidiabetics grew at 61.1% PPG.
• Top Corporations: Eli Lilly led with 83.8% PPG growth, driven by Mounjaro (146.4%), Cialis (7.2%), and Taltz (20.8%).

Tunisia

• Value Growth: 9.3% PPG, with Retail and Hospital channels growing at 8.4% and 11.7% PPG respectively.
• Top Corporations: Medis leads with 6.7% market share. Unimed Tunis is the fastest-growing with 65.3% PPG.

Algeria

• Value Growth: 7.3% PPG, driven by local/regional players.
• Top TAs: Lipid Regulators grew at 13.5% PPG.
• Top Corporation: MS Pharma leads with 7.3% market share and 14.7% PPG growth.

Egypt

• Value Growth: -5.5% PPG, but Retail channel contributed 81.7% of total unit sales.
• Top TA: Systemic Antibacterials (10.7% units share), while Antihypertensives was the fastest-growing TA at 0.3% PPG.
• Top Corporations: Pharco leads with 7.6% share, and Sanofi is the fastest-growing with 19.1% PPG.

Jordan

• Value Growth: 2.3% PPG, with Novo Nordisk leading the growth at 24.6% PPG.
• Top Products: Ozempic (89.3% PPG), Saxenda (-48.9% PPG), and Norditropin (14.3% PPG).

Kuwait

• Value Growth: 4.0% PPG, with LPO channel contributing 74.7% of total sales.
• Top Corporation: Novartis leads with 8.2% share and 38.8% PPG growth, driven by Cosentyx (139.4%), Xolair (10.3%), and Entresto (31.5%).

Lebanon

• Value Growth: 25.6% PPG, with GSK leading at 43.1% PPG.
• Top Corporation: Julphar is the fastest-growing with 65.5% PPG.

South Africa

• Value Growth: 1.6% PPG, with Retail accounting for 82.3% of total sales.
• Top Corporations: Adcock Ingram leads with 9.4% share, and Cipla is the fastest-growing at 9.9% PPG.

Top Therapy Areas (TAs)

Market Share by Corporations

• MNCs: Account for 59% of total value sales, growing at 11.6% PPG.
• Local/Regional Companies: Account for 41% of total value sales, growing at 13.1% PPG.
• Top Corporations:
  • Eli Lilly: Fastest-growing at 100.6% PPG.
  • Novartis: Second-fastest-growing at 38.8% PPG.
  • GSK: Leading in Lebanon with 43.1% PPG.
  • Sanofi: Top in FWA and leading in Egypt with 19.1% PPG.
  • Hikma Pharma: Leading in KSA with 4.1% PPG growth.

Future Forecasts

• By 2028, the global pharmaceutical business is expected to reach $2.27 T, with MEA collectively reaching $63.3 B.
• MEA Growth Rate: Projected at 4.3% CAGR from 2018–2023 and 4.3% CAGR for the period 2023–2028.
• Regional Growth Projections:
  • Middle East: 7.7% CAGR
  • Africa: 5.7% CAGR

Data Coverage and Methodology

• IQVIA Data Coverage: Over 200 collaborating data suppliers in the ME region (7 countries since 1971 and 9 countries in total).
• Sell-in Data: Collected from 35 distributors/suppliers and 400 pharmacies, with 65% actual and 35% projected data.
• ESWT (Egypt Switch Tracker): Launched in Jan 2024, provides insights into brand switching behavior across pharmacies.
• SSS (Sub National Sector Split): Launched in Q1-2024, offers more granular analysis of sales by individual pharmacies, chain pharmacies, stores, and private hospitals.
• Pharma Sell Out Data: Collected from 400 pharmacies across Jordan, covering 5 M transactions with monthly releases.
• Autoimmune + MS Insights: A cross-sectional survey of physicians, covering 13 diseases and 4 countries (France, Spain, UK, KSA), with dynamic data visualization and analysis.

Summary of Key Insights

• Retail Channel: Dominates the MEA region with strong growth and a significant share of total sales.
• Local/Regional Growth: Outpaced MNCs in several countries, including UAE, Algeria, and Tunisia.
• Top TAs: Alimentary Tract, Metabolism and Blood + B. Forming Organs are the fastest-growing TAs.
• Fastest-Growing Corporations: Eli Lilly, Novartis, and Julphar are among the top performers.
• Data Collection: Comprehensive and multi-source, including private, LPO, and institutional data.

Conclusion

The MEA pharmaceutical market is experiencing mixed growth, with significant value growth in most countries and stable volume growth. Retail remains the dominant channel, while local and regional companies are gaining traction. Key TAs such as Alimentary Tract and Blood + B. Forming Organs are driving growth, and major corporations like Eli Lilly and Novartis are leading the way. The report also highlights the importance of data collection and analysis in shaping market strategies, especially through initiatives like Autoimmune + MS Insights and ESWT.